Pharmacogenomic variants are known to display differences in frequencies across the populations and many world regions have been underrepresented in past research. These differences and disparities have important clinical implications.
By studying the full spectrum of diversity in drug-related genes in representative cohorts, we have highlighted the importance of rare functional variation in pharmacogenomics. Further, we have shown that globally 97% of individuals carry clinically-meaningful pharmacogenomic markers related to drug safety.
Ongoing studies include the analysis of large numbers of exomes from patients who have experienced rare adverse drug reactions.